ADMA Biologics, Inc. (ADMA)
Automate Your Wheel Strategy on ADMA
With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADMA
- Rev/Share 1.932
- Book/Share 1.5705
- PB 11.296
- Debt/Equity 0.2196
- CurrentRatio 6.5762
- ROIC 0.4874
- MktCap 4235141160.0
- FreeCF/Share 0.3813
- PFCF 46.7161
- PE 20.4
- Debt/Assets 0.1606
- DivYield 0
- ROE 0.7239
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Negative
Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.
Read More
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
Read More
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
Read More
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Read More
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repurchase program.
Read More
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.
Read More
ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025. At this time, all participants are in a listen-only mode.
Read More
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.
Read More
3 Mid-Cap Medical Stocks Outperforming the Market
Published: May 06, 2025 by: MarketBeat
Sentiment: Positive
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.
Read More
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Read More
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
Read More
Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
Read More
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Read More
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Five mid-cap high-flying stocks to buy are: ADMA, FCFS, LRN, LTH, NFG.
Read More
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla.
Read More
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity
Read More
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
Read More
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA Biologics Inc (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Will ADMA Biologics Stock Continue Its Momentum in 2025?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
Read More
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views?
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Block & Leviton is investigating ADMA Biologics for potential securities fraud. Investors who lost money in ADMA should contact the firm to learn more.
Read More
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET.
Read More
About ADMA Biologics, Inc. (ADMA)
- IPO Date 2013-10-17
- Website https://www.admabiologics.com
- Industry Biotechnology
- CEO Mr. Adam S. Grossman
- Employees 685